A comparative study of melanopsin-mediated pupillary responses among diseases with concomitant circadian rhythm sleep/wake disorders

Kitamura Shingo0 个研究点目标入组 100 人开始时间: 2023年6月2日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•DSWPD patients: 1) Participants who are between 16 and 29 years old at the time of consent. 2) Participants who meet DSM-5 or ICSD-3 diagnostic criteria for DSWPD
•Healthy controls of DSWPD patients: 1) Participants who are between 16 and 29 years old at the time of consent.
•AD Spectrum Patients: 1) Participants who are between 60 and 80 years old at the time of consent. 2) Participants who meet the diagnostic criteria for AD Spectrum (Mild AD, MCI, Preclinical AD) 3) Participants who fully understand the study and give their free and voluntary written consent.
•Healthy controls of AD spectrum patients: 1) Participants who are between 60 and 80 years old at the time of consent. 2) Participants who fully understand the study and give their free and voluntary written consent

•DSWPD patients: 1) Participants with neurodegenerative diseases. 2) Participants with abnormal color vision. 3) Participants with darkness phobia. 4) Other subjects deemed inappropriate by the principal investigator.
•Healthy controls of DSWPD: 1) Participants with psychiatric disorders. 2) Participants with neurodegenerative disorders. 3) Participants with abnormal color vision. 4) Participants with darkness phobia. 5) Other subjects deemed inappropriate by the principal investigator.
•AD Spectrum Patients: 1) Participants with neurodegenerative diseases other than AD Spectrum. 2) Participants with abnormal color vision. 3) Those with darkness phobia. 4) Others whom the principal investigator deems inappropriate.
•Healthy controls of AD spectrum: 1) Participants with psychiatric disorders. 2) Participants with neurodegenerative disorders. 3) Participants with abnormal color vision. 4) Participants with darkneess phobia. 5) Other subjects deemed inappropriate by the principal investigator.

发起方

Kitamura Shingo